Total Liabilities
Bristol-Myers Squibb Total Liabilities decreased by 7.2% to $66.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.5%, from $74.98B to $66.37B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows a downward trend with a -2.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may indicate aggressive debt-funded expansion or rising operational costs, while a decrease suggests debt repayment or reduced leverage.
Detailed definition
Total liabilities represent the aggregate of all current and non-current financial obligations owed by the company to ex...
Peer comparison
Large pharmaceutical firms typically carry significant debt loads to fund R&D and acquisitions, making this a key metric for assessing solvency relative to peers.
total_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $73.92B | $73.61B | $73.31B | $71.39B | $67.7B | $65.46B | $65.7B | $62.4B | $61.46B | $62.2B | $65.67B | $82.48B | $77.58B | $76.47B | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B | $66.37B |
| QoQ Change | — | -0.4% | -0.4% | -2.6% | -5.2% | -3.3% | +0.4% | -5.0% | -1.5% | +1.2% | +5.6% | +25.6% | -5.9% | -1.4% | -0.3% | -1.6% | +2.9% | +1.4% | -8.6% | -7.2% |
| YoY Change | — | — | — | — | -8.4% | -11.1% | -10.4% | -12.6% | -9.2% | -5.0% | -0.0% | +32.2% | +26.2% | +22.9% | +16.1% | -9.1% | -0.5% | +2.4% | -6.1% | -11.5% |
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's total liabilities?
- Bristol-Myers Squibb (BMY) reported total liabilities of $66.37B in Q1 2026.
- How has Bristol-Myers Squibb's total liabilities changed year-over-year?
- Bristol-Myers Squibb's total liabilities decreased by 11.5% year-over-year, from $74.98B to $66.37B.
- What is the long-term trend for Bristol-Myers Squibb's total liabilities?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's total liabilities has grown at a -2.4% compound annual growth rate (CAGR), from $80.6B to $71.53B.
- What does total liabilities mean?
- The total amount of money the company owes to creditors and other parties.